In California, Codexis announced that research conducted by Merck and Codexis scientists to develop a highly efficient, enzyme-based production method for a key intermediate in the production of boceprevir has been recently published in the Journal of the American Chemical Society.
Boceprevir is the active ingredient in Merck’s Victrelis capsules. Using their proprietary CodeEvolver technology, Codexis and Merck created a custom enzyme or biocatalyst, resulting in a new method increased chemical intermediate yield 150 percent over the previous process.
More background on the story from the Digest
Category: Chems & Materials